isoniazid, streptomycin and pyrazinamide, and isoniazid for 4 months. Considering the small number of patients studied, we concluded very little from this study about the efficacy of ciprofloxacin for tuberculosis treatment.
We are concerned about the erroneous conclusion that ciprofloxacin appearing to be an appropriate drug for tuberculosis treatment will be accepted by poorly informed physicians. This would only increase the problems of inappropriate treatment and failure to ensure that patients are cured with effective treatment regimens. Nowhere are those problems more critical than in India. Recent studies in Bombay and Southern India have shown widespread misapplication of tuberculosis treatment by private practitioners6 and high rates of treatment failure in program settings.7 Rather than needing new drugs for tuberculosis, India and other developing countries throughout the world badly need proper application of tuberculosis treatment regimens proven to be effective in both clinical trials and program settings.8
